Clinical Trial: Phase I Study of HRS-1635 in B-cell Malignancies

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07583212) titled 'Phase I Study of HRS-1635 in B-cell Malignancies' on May 07.

Brief Summary: The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-1635 in participants with B-cell malignancy.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: B-cell Malignancy

Intervention: DRUG: HRS-1635

HRS-1635

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chengdu Suncadia Medicine Co., Ltd.

Published by HT Digi...